-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Sabalenka, top WTA stars urge Slams to revive 'stalled' negotiations
-
5 killed in Afghan-Pakistan border fire despite peace talks: official
-
Trump unveils deals to lower costs of some weight-loss drugs
-
Controversial Canadian ostrich cull order will go ahead
-
Mexico's Sheinbaum to boost reporting of sexual abuse after being groped
-
Zuckerbergs put AI at heart of pledge to cure diseases
-
Crypto giant Coinbase fined in Ireland for rule breaches
-
Lawson relieved as he reveals FIA support following Mexican near-miss
-
US set for travel chaos as flights cut due to govt shutdown
-
Sabalenka and Pegula book their spots in WTA Finals last four
-
'Our brother-in-law': Arab world embraces New York's new mayor
-
France boss Deschamps would prefer to 'avoid playing' on Paris attacks anniversary
-
Pegula sweeps past Paolini to reach WTA Finals last four
-
Bolivian ex-president Anez leaves prison after sentence annuled
-
Stocks slide as investors weigh data, interest rate cuts
-
UN says 2025 to be among top three warmest years on record
-
Fleetwood and Lowry lift each other into Abu Dhabi lead
-
Fleetwod and Lowry lift each other into Abu Dhabi lead
-
New Zealand make changes after Barrett brothers' injuries as Scotland drop Van der Merwe
-
Dallas Cowboys' Marshawn Kneeland dies at 24: franchise
-
Pegula dispatches Paolini to keep WTA Finals semis bid alive
-
Dutch giants Ajax sack coach John Heitinga
-
Kirchner on trial in Argentina's 'biggest ever' corruption case
-
Amorim urges Man Utd to 'focus on future' after Ronaldo criticism
-
US judge drops criminal charges against Boeing over 737 MAX 8 crashes
-
World must face 'moral failure' of missing 1.5C: UN chief to COP30
-
UK grandmother leaves Indonesia death row to return home
-
Garcia broken nose adds to Barca defensive worries
-
Tight UK security ahead of match against Israeli club
-
Ethiopia's Afar region says attacked by Tigray forces
-
Nancy Pelosi, Democratic giant, Trump foe, first woman House speaker, to retire
-
Israel strikes Hezbollah targets in Lebanon
-
Burger strikes as South Africa restrict Pakistan to 269-9 in second ODI
-
Stocks slip as investors weigh earnings, tariffs
-
Police say 19 held after raid at Swedish start-up Stegra to be deported
-
Kante returns as France seek to clinch World Cup berth
-
Marcus Smith starts at full-back as England ring changes for Fiji
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
P.Mathewson--AMWN